Key facts
- Merida Biosciences’s last known valuation is $228.0M (Apr 2025).
- It has raised $154.0M across 1 recorded rounds; the latest was Later Stage VC ($121.0M) in Apr 2025.
- Notable investors include GV, The Engine, Perceptive Advisors, Bain Capital Life Sciences, Third Rock Ventures — 6 tracked in total.
- Status: Privately Held (backing).
Leadership
- Adam TownsendPresident & Chief Executive Officer
- Dario GutierrezFounder & Chief Scientific Officer
- Dodzie SogahChief Operating Officer
- Allison DorvalChief Financial Officer
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Merida Biosciences
Funding rounds
1 roundsAbout Merida Biosciences
Developer of targeted immunotherapies designed for the treatment of autoimmune and allergic diseases. The company's platform focuses on the selective elimination of disease-causing antibody-producing cells while sparing healthy immune function, enabling healthcare providers to address underlying disease mechanisms more effectively.
- Industry
- Biotech
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2022
- Employees
- 45
- Website
- meridabio.com/
- Ownership
- Privately Held (backing)
Merida Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Merida Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Merida Biosciences in its N-PORT filings yet. We sweep new filings monthly.